Terms: = Lung cancer AND Cytokeratin fragment 21-1
21 results:
1. IR808@MnO nano-near infrared fluorescent dye's diagnostic value for malignant pleural effusion.
Wang X; Yan X; Zhang Z; Xu C; Du F; Xie Y; Yin X; Lei Z; Jiang Y; Yang W; Zhou X; Wang Y
Respir Res; 2024 Jan; 25(1):22. PubMed ID: 38195540
[TBL] [Abstract] [Full Text] [Related]
2. Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
Zhou D; Zhai X; Zhang R
PLoS One; 2023; 18(9):e0291461. PubMed ID: 37699023
[TBL] [Abstract] [Full Text] [Related]
3. Plasmonic metasurface enhanced by nanobumps for label-free biosensing of lung tumor markers in serum.
Wang Z; Chen W; Liu X; Lin S; Deng B; Shen J; Li F; Zhu J
Talanta; 2023 Nov; 264():124731. PubMed ID: 37285700
[TBL] [Abstract] [Full Text] [Related]
4. Recent progress of biosensors for the detection of lung cancer markers.
Chen S; Li M; Weng T; Wang D; Geng J
J Mater Chem B; 2023 Jun; 11(25):5715-5747. PubMed ID: 37264815
[TBL] [Abstract] [Full Text] [Related]
5. CircFOXP1: A novel serum diagnostic biomarker for non-small cell lung cancer.
Luo Y; Zhang Q; Lv B; Shang Y; Li J; Yang L; Yu Z; Luo K; Deng X; Min L; Zhu T
Int J Biol Markers; 2022 Mar; 37(1):58-65. PubMed ID: 35072545
[TBL] [Abstract] [Full Text] [Related]
6. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
[TBL] [Abstract] [Full Text] [Related]
7. Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations.
Lee HW; Park YS; Park S; Lee CH
Sci Rep; 2020 Sep; 10(1):14933. PubMed ID: 32913267
[TBL] [Abstract] [Full Text] [Related]
8. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations.
Debeljak Ž; Dundović S; Badovinac S; Mandić S; Samaržija M; Dmitrović B; MiloÅ¡ M; MariÄić L; Å erić V; Buljanović V
Clin Chem Lab Med; 2018 Jul; 56(8):1328-1335. PubMed ID: 29648993
[TBL] [Abstract] [Full Text] [Related]
9. Extent and cost of inappropriate use of tumour markers in patients with pulmonary disease: a multicentre retrospective study in Shanghai, China.
Zhang H; Song Y; Zhang X; Hu J; Yuan S; Ma J
BMJ Open; 2018 Feb; 8(2):e019051. PubMed ID: 29490961
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Carvalho S; Troost EG; Bons J; Menheere P; Lambin P; Oberije C
Radiother Oncol; 2016 Jun; 119(3):487-94. PubMed ID: 27139126
[TBL] [Abstract] [Full Text] [Related]
11. Quantification of serum MET in non-small-cell lung cancer and its clinical significance.
Li D; Li F; Wu Y; Zhou D; Chen H
Clin Biochem; 2015 Feb; 48(3):110-4. PubMed ID: 25489726
[TBL] [Abstract] [Full Text] [Related]
12. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases.
Xu RH; Liao CZ; Luo Y; Xu WL; Li K; Chen JX; Huang YF; Chen YC; Zhu L; Yuan WB
Clin Chim Acta; 2015 Feb; 440():188-92. PubMed ID: 25304744
[TBL] [Abstract] [Full Text] [Related]
13. [Value of low-dose spiral computed tomography in lung cancer screening].
Zhang Y; Hong QY; Shi WB; Ou JX; Yang DW; Hu J; Bai CX; Zeng MS; Chen G
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3011-4. PubMed ID: 24417917
[TBL] [Abstract] [Full Text] [Related]
14. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer.
Wu Y; Du X; Xue C; Li D; Zheng Q; Li X; Chen H
Med Oncol; 2013 Dec; 30(4):737. PubMed ID: 24126941
[TBL] [Abstract] [Full Text] [Related]
15. Clinical significance of serum transforming growth factor-β1 in lung cancer.
Hou YL; Chen H; Dong ZH; Xue CJ; Wu YF; Luo HX; Wu YC; Li CH
Cancer Epidemiol; 2013 Oct; 37(5):750-3. PubMed ID: 23727122
[TBL] [Abstract] [Full Text] [Related]
16. Predictive factors for node metastasis in patients with clinical stage I non-small cell lung cancer.
Cho S; Song IH; Yang HC; Kim K; Jheon S
Ann Thorac Surg; 2013 Jul; 96(1):239-45. PubMed ID: 23673071
[TBL] [Abstract] [Full Text] [Related]
17. Quantification of serum HBXAP DNA in lung cancer patients by quantitative fluorescent polymerase chain reaction.
Hou YL; Chen H; Ge MJ; Li FZ; Xue CJ; Wu YF; Luo HX
Mol Biol Rep; 2013 Jun; 40(6):4091-6. PubMed ID: 23456648
[TBL] [Abstract] [Full Text] [Related]
18. Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
Zhang W; Guo N; Yu C; Wang H; Zhang Y; Xia H; Yu J; Lu J
Tumour Biol; 2012 Dec; 33(6):2209-16. PubMed ID: 22890830
[TBL] [Abstract] [Full Text] [Related]
19. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.
Bigbee WL; Gopalakrishnan V; Weissfeld JL; Wilson DO; Dacic S; Lokshin AE; Siegfried JM
J Thorac Oncol; 2012 Apr; 7(4):698-708. PubMed ID: 22425918
[TBL] [Abstract] [Full Text] [Related]
20. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract] [Full Text] [Related]
[Next]
